Ensemble Discovery and Pfizer have entered a strategic alliance, to discover and develop a new class of oral drugs developed by Ensemble to address diseases that cannot be modulated effectively by traditional small molecule pharmaceuticals.

The collaboration will deploy Ensemble’s proprietary drug discovery platforms, which use Ensemblins, synthetic macrocycles designed to bridge the gap between commonly used oral small molecules and large protein biologics.

Ensemble Discovery CSO Nick Terrett said that there is a growing recognition of the need for novel chemistry to attack the many targets that do not lend themselves to conventional small molecule or biologic drugs.

“Our progress has demonstrated the power of the Ensemblins to address those targets, as our leading projects have advanced to demonstrate oral efficacy in preclinical disease models,” Terret said.

Under the agreement Pfizer will provide upfront and research payments to Ensemble and will have the right to develop and commercialise any products arising from the collaboration.

In addition, Ensemble will receive development milestones plus royalties based on worldwide sales of any drugs emerging from the alliance commercialised by Pfizer.